Cargando…
Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles()
Pancreatic cancer remains one of the most intractable cancers, with a dismal prognosis reflected by a 5-year survival of ~ 6%. Since early disease symptoms are undefined and specific biomarkers are lacking, about 80% of patients present with advanced, inoperable tumors that represent a daunting chal...
Autores principales: | Blanco, Victor M., Latif, Tahir, Chu, Zhengtao, Qi, Xiaoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486738/ https://www.ncbi.nlm.nih.gov/pubmed/26055177 http://dx.doi.org/10.1016/j.tranon.2015.03.011 |
Ejemplares similares
-
Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles
por: Blanco, Víctor M., et al.
Publicado: (2016) -
Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors
por: Blanco, Víctor M., et al.
Publicado: (2014) -
Enhanced phosphatidylserine-selective cancer therapy with irradiation and SapC-DOPS nanovesicles
por: Davis, Harold W., et al.
Publicado: (2019) -
SapC-DOPS – a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy
por: N’Guessan, Kombo F., et al.
Publicado: (2020) -
Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles
por: Davis, Harold W., et al.
Publicado: (2020)